Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Posts 21 Percent Gain in Q2 Revenues

NEW YORK, July 29 (GenomeWeb News) - Lexicon Genetics today reported second quarter revenues of $10.8 million, up 21 percent from 2003 second quarter revenues of $8.9 million.

 

The Woodlands, Texas-based firm primarily attributed the increase in revenues to a collaborative neuroscience research pact with Bristol-Myers Squibb.

 

For the quarter ended June 30, 2004, Lexicon Genetics reported a net loss of $16.8 million, or $.26 per share, down from the net loss of $17.6 million, or $.34 per share, reported in the second quarter of 2003. The firm's research and development expenses grew to $22.6 million from $20.8 million in the comparable period a year ago.

 

At the end of the second quarter, Lexicon Genetics held cash and investments of $104.3 million, compared to $145.4 million at the end of its first quarter.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.